Navigation Links
Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD
Date:9/22/2010

per year."

The phase 2 study enrolled 155 type 2 diabetes patients (51-53 patients/arm) across 50 centers in the United States on a stable treatment regimen of metformin. The study compared six different regimens to find the optimal dose range and regimen to take into phase 3:

  • ITCA 650 20 mcg/day for 24 weeks
  • ITCA 650 40 mcg/day for 24 weeks
  • ITCA 650 20 mcg/day for weeks 1 -12 followed by ITCA 650 60 mcg/day for weeks 13 -24
  • ITCA 650 40 mcg/day for weeks 1 -12 followed by ITCA 650 80 mcg/day for weeks 13 -24
  • Exenatide injection for weeks 1 -12 followed by ITCA 650 40 mcg/day for weeks 13 -24
  • Exenatide injection for weeks 1 -12 followed by ITCA 650 60 mcg/day for weeks 13 -24

  • Summary of week 12 resultsTreatment with ITCA 650 at doses of 20 mcg/day and 40 mcg/day resulted in significant reductions in HbA1c at week 12.  Initiating treatment with ITCA 650 20 mcg/day resulted in less frequent and less persistent nausea compared with ITCA 650 40 mcg/day and exenatide injection.  Nausea rates among patients receiving ITCA 650 at 40 mcg/day were similar to those receiving twice-daily injection of exenatide at 10 mcg BID.

    The phase 2 study also incorporated a quality of life (QOL) assessment (DM-SAT) completed by each patient prior to initiating treatment, at treatment week 8 and again at treatment week 20.  The results of week 8 assessment suggest that patients receiving either dose of ITCA 650 experienced significantly greater improvement in their quality of life compared to patients receiving twice-daily injections of exenatide.

    Summary of week 12 resultsTreatment Arms
    Weeks 1 – 12

    ITCA 650 20 mcg/d

    ITCA 650 40 mcg/dExenatide InjectionMean baseline HbA1c (%)

    7.90

    8.00

    8.01Mean week 12 HbA1c (%)

    6.94

    6.96

    7.19Mean change

    -0.96*

    -1.04*

    -0.82*Nausea ratesweek 1

    25%

    37%'/>"/>

    SOURCE Intarcia Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
    2. Intarcia Therapeutics Names Kurt Graves Executive Chairman to Advance Strategic Interests and Broaden Commercial Goals
    3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
    4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
    5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
    6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
    7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
    8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
    9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
    10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
    11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... Sept. 2, 2015  Seeger Weiss LLP is reporting ... will commence October 13, 2015. Since ... fast-track approval program, Zimmer NexGen knee implant surpassed FDA ... that companies provide evidence that the product is substantially ... to gain permissions. In 2001, Zimmer ...
    (Date:9/2/2015)... Sept. 2, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... Chief Financial Officer of Neurocrine Biosciences, will be presenting ... New York City . The live ... ET (8:25am PT).  The presentation will be webcast and ... http://www.neurocrine.com .   Listeners are encouraged to ...
    (Date:9/2/2015)... -- Demers Ambulances is proud to announce it has signed ... the states of Mississippi , ... "This will enable Demers to effectively meet the ... Vice-President for Demers Ambulances. "Emergency Equipment Professionals has three service ... Alabama , giving them a strategic advantage. Local ...
    Breaking Medicine Technology:Seeger Weiss LLP Reports That Zimmer NexGen Knee MDL Bellwether Trial Date Set For October 13, 2015 2Demers Ambulances has named Emergency Equipment Professionals (EEP) Inc. as their dealer for the states of MS, AL and TN 2
    ... call Monday, March 10, 2008 at 8:30am, NEW ... ) today announced top-line results from its SUN-MICRO,Phase 3 ... nephropathy. The Company announced that this Phase 3 clinical,trial ... which was to,increase the proportion of patients that achieve ...
    ... Hardening Affects of the,Devastating Disease, CHICAGO, March ... the effects of an anti-cancer drug to treat,patients ... leads to hardening and tightening of the skin ... in the United States and,can often attack the ...
    Cached Medicine Technology:Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint 2Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint 3Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint 4Northwestern Memorial Study Tests Cancer Drug on Scleroderma Patients 2
    (Date:9/3/2015)... ... ... ProScrub is a set of automated tools that allow Final Cut Pro ... without the use of keyframes. Utilize ProScrub's powerful sliders to determine the number ... to energetic video productions. ProScrub is a Final Cut Pro X ...
    (Date:9/3/2015)... ... September 03, 2015 , ... AvePoint, the ... AvePoint Perimeter Service Pack (SP) 4 – AvePoint’s solution for facilitating two-way collaboration ... “KMWorld 2015 Trend-Setting Product”. This is the fifth consecutive year an AvePoint ...
    (Date:9/3/2015)... ... 2015 , ... Representatives with State Farm Agent EJ Roberts ... Gulf Babypalooza on September 19, 2015. , “We will be providing information to ... We will be discussing setting up college funds, offering information specific to their ...
    (Date:9/3/2015)... ... September 03, 2015 , ... When looking at the types of people who have ... of two categories: those that have a weak appetite or those that have a fast ... to gain weight, CB-1 Weight Gainer gives three tips for slowing down metabolism. , The ...
    (Date:9/3/2015)... , ... September 03, 2015 , ... James Earl Jones ... workplace wellness. In this episode, James Earl Jones will introduce a segment that discusses ... unhealthy workplace and how workplace wellness can be fostered in any working environment. , ...
    Breaking Medicine News(10 mins):Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 2Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 3Health News:AvePoint Perimeter Named a “KMWorld 2015 Trend-Setting Product” 4Health News:State Farm Agent EJ Roberts to Help Expecting Mothers at the Mississippi Gulf Babypalooza 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 2Health News:CB-1 Weight Gainer Gives Three Tips for Slowing Down Metabolism 3Health News:James Earl Jones Hosts a New "Voices In America" Piece on Making the Workplace Healthier 2
    ... Lay, the founder of Enron, who was admitted at the ... the early morning due to a heart attack//. ... had succumbed to his illness just months before his impending ... founder of the Enron Corp. was convicted on 10 counts ...
    ... in New Brunswick, New Jersey have reported that breast ... wetting //as children since they seem to have a ... inferring that breast-feeding protects against bed-wetting and our results ... added that there was sufficient evidence that bed-wetting can ...
    ... an important move that will benefit poor patients, the Centre ... prestigious All India Institute// of Medical Sciences (AIIMS). ,The ... was taken at a meeting of the AIIMS Institute Body ... to be rolled back., ,"The Union Health Ministry has ...
    ... attractive sachets is fast replacing the traditional paan in Pakistan, ... that both are banned, says a media report. ,In ... gutka, is being marketed daily. ,The government ... "too great". "In fact it is registered as an important ...
    ... of relieving pain, say researchers from the University College London. ... understand the behavior of pain receptors within cells. ... effect. Scientists rated the benefits of heat for pain relief ... turned off at the molecular level, when exposed to heat. ...
    ... (MIMR) have developed a new machine, named near-infrared spectroscopy, ... ,Although it was the first of its ... fluctuating BP and brain oxygen levels of a preterm ... of Medical Research (MIMR) are carrying out studies to ...
    Cached Medicine News:Health News:Preterm Babies Benefited from a New NI Spectroscopy 2
    ... is a CO2 laser system with ... Its functions in continuous and super-pulsed ... extreme laser intervention delicacy. Excellent as ... it comes with a large LCD ...
    Auto Refkeratomoeter...
    Developed to meet the infusion needs in NICU, Anesthesia and Critical Care, the AUTO SYRINGE AS50 Infusion Pump delivers precise, controlled infusions....
    The FLO-GARD 6201 Volumetric Infusion Pump and the FLO-GARD 6301 Dual-Channel Volumetric Infusion Pump are industry standard in standard set infusion pump technology....
    Medicine Products: